CN105418608B - 7 benzos [b] [1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide and its production and use - Google Patents
7 benzos [b] [1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide and its production and use Download PDFInfo
- Publication number
- CN105418608B CN105418608B CN201510870314.1A CN201510870314A CN105418608B CN 105418608 B CN105418608 B CN 105418608B CN 201510870314 A CN201510870314 A CN 201510870314A CN 105418608 B CN105418608 B CN 105418608B
- Authority
- CN
- China
- Prior art keywords
- phenanthroline
- benzos
- compound
- reaction
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 title claims abstract description 19
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 title claims abstract 20
- 229940049706 benzodiazepine Drugs 0.000 title claims abstract 12
- 125000003368 amide group Chemical group 0.000 title claims abstract 10
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 title claims abstract 10
- 125000005605 benzo group Chemical group 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 claims abstract description 5
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims abstract 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 23
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- -1 compound N- quinolyl ortho-aminobenzoic acids Chemical class 0.000 claims description 19
- 239000007787 solid Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 8
- ALXBXKJAVGIBDQ-UHFFFAOYSA-N 2-(quinolin-2-ylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=C(C=CC=C2)C2=N1 ALXBXKJAVGIBDQ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- XRXMNWGCKISMOH-UHFFFAOYSA-N 2-bromobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Br XRXMNWGCKISMOH-UHFFFAOYSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 2
- 229960003350 isoniazid Drugs 0.000 claims description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 3
- 150000005012 8-aminoquinolines Chemical class 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229910019213 POCl3 Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000010813 municipal solid waste Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 8
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 150000001251 acridines Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- UQCFNWNKJIRYMN-UHFFFAOYSA-N 7-chlorobenzo[b][1,10]phenanthroline Chemical compound C1=CC2=CC=CN=C2C2=C1C(Cl)=C(C=CC=C1)C1=N2 UQCFNWNKJIRYMN-UHFFFAOYSA-N 0.000 description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical compound C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- QPNTVQDJTQUQFX-UHFFFAOYSA-N benzo[b][1,10]phenanthroline Chemical group C1=CN=C2C3=NC4=CC=CC=C4C=C3C=CC2=C1 QPNTVQDJTQUQFX-UHFFFAOYSA-N 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000005918 in vitro anti-tumor Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical compound N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
技术领域technical field
本发明涉及医药技术领域,特别涉及抗肿瘤药物技术领域,具体是一种具有抗肿瘤活性的7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰胺基硫脲的制备方法和用途The present invention relates to the technical field of medicine, in particular to the technical field of antitumor drugs, in particular to a preparation method of 7-benzo[b]-[1,10]phenanthroline pyridine carboxamide thiourea with antitumor activity and use
背景技术Background technique
吖啶是一类受到广泛关注的含氮有机杂环化合物,因其结构为大环共轭体系,具刚性平面结构,可作为DNA等大分子的嵌入体,在抗肿瘤、抗病毒、抗疟疾、抗菌、生物荧光探针和治疗艾滋病等方面均表现出很强的生理活性,人们已从天然产物中提取或采用化学合成的方法获得了大量的吖啶类化合物,研究了它们的药理活性和作用机理。为了改进它对DNA的亲和性能、多种酶的抑制性能和细胞毒性等,对其结构改造进行了不断的探索与改进,本发明的创新之处在于通过在苯并[b]-[1,10]邻菲咯啉环的7-位上连接活性基团酰胺基硫脲结构,合成新型吖啶衍生物,该衍生物目前尚未有报道。Acridine is a class of nitrogen-containing organic heterocyclic compounds that has received widespread attention. Because its structure is a macrocyclic conjugated system with a rigid planar structure, it can be used as an intercalator for macromolecules such as DNA. It has anti-tumor, anti-virus, and anti-malarial , antibacterial, bioluminescent probes and the treatment of AIDS, etc. have shown strong physiological activities. People have obtained a large number of acridine compounds from natural products or by chemical synthesis. Their pharmacological activities and mechanism of action. In order to improve its affinity to DNA, the inhibitory performance of various enzymes and cytotoxicity, etc., its structural transformation has been continuously explored and improved. The innovation of the present invention lies in the use of benzo[b]-[1 , 10] The 7-position of the o-phenanthroline ring is connected with an active group amidothiourea structure to synthesize a novel acridine derivative, which has not yet been reported.
发明内容Contents of the invention
本发明的目的是为了克服上述问题,提供一种具有抗肿瘤活性的化合物,在苯并[b]-[1,10]邻菲咯啉环的7-位上连接活性基团酰胺基硫脲结构,合成新型吖啶衍生物,具有极强的抗肿瘤活性,能够应用于抗肿瘤药物的制备中。The purpose of the present invention is to overcome the above problems and provide a compound with anti-tumor activity, which is connected with an active group amidothiourea at the 7-position of the benzo[b]-[1,10]phenanthroline ring Structure, synthesis of novel acridine derivatives, which have strong anti-tumor activity and can be used in the preparation of anti-tumor drugs.
本发明的另一个目的是为了提供一种制备具有抗肿瘤活性药物的方法,对其结构改造改进了抗肿瘤活性药物对DNA的亲和性能、多种酶的一致性能和细胞毒性。Another object of the present invention is to provide a method for preparing a drug with anti-tumor activity, and its structural modification improves the affinity of the anti-tumor drug to DNA, the consistency of various enzymes, and the cytotoxicity.
本发明的另一个目的是为了提供一种7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰 胺基硫脲在制备抗肿瘤药物的应用。Another object of the present invention is to provide a kind of 7-benzo [b]-[1,10] o-phenanthroline pyridine carboxamide thiourea in the preparation of antitumor drug application.
为了实现本发明的目的和其他优点,提供一种7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰胺基硫脲,其结构式为:In order to realize the purpose and other advantages of the present invention, a kind of 7-benzo [b]-[1,10] o-phenanthroline pyridine carboxamide thiourea is provided, and its structural formula is:
所述7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰胺基硫脲分子式为C23H16N6OS,相对分子量为424.48,理化性质为:黄色粉末,m.p.175-181℃;1H NMR(DMSO-d6,400M Hz),δ:12.89(br,s,1H,-NH),12.41(br,s,1H,-NH),11.07(br,s,1H,-NH),10.99(s,1H,ArH),10.22(d,1H,J=9.0,ArH),9.09(d,1H,J=8.5,ArH),8.82(s,1H,ArH),8.64(d,2H,J=7.2,ArH),8.47(d,1H,J=7.2,ArH),8.24-8.36(m,2H,ArH),7.86-7.96(m,2H,ArH),7.83(d,1H,J=7.2,ArH),7.77(d,1H,J=7.2,ArH),7.66-7.74(m,2H,ArH);13C NMR(DMSO-d6,100MHz),δ189.70,170.21,150.34,149.89,145.21,134.38,133.78,133.42,132.18,131.29,130.55,130.21,129.67,129.27,128.54,127.64,126.79,124.35,123.78。The 7-benzo[b]-[1,10]phenanthroline pyridine carboxamide thiourea has a molecular formula of C 23 H 16 N 6 OS, a relative molecular weight of 424.48, and physical and chemical properties: yellow powder, mp175-181 ℃; 1 H NMR (DMSO-d 6 , 400M Hz), δ: 12.89 (br, s, 1H, -NH), 12.41 (br, s, 1H, -NH), 11.07 (br, s, 1H, -NH) NH), 10.99(s, 1H, ArH), 10.22(d, 1H, J=9.0, ArH), 9.09(d, 1H, J=8.5, ArH), 8.82(s, 1H, ArH), 8.64(d , 2H, J=7.2, ArH), 8.47(d, 1H, J=7.2, ArH), 8.24-8.36(m, 2H, ArH), 7.86-7.96(m, 2H, ArH), 7.83(d, 1H , J=7.2, ArH), 7.77 (d, 1H, J=7.2, ArH), 7.66-7.74 (m, 2H, ArH); 13 C NMR (DMSO-d 6 , 100MHz), δ189.70, 170.21, 150.34, 149.89, 145.21, 134.38, 133.78, 133.42, 132.18, 131.29, 130.55, 130.21, 129.67, 129.27, 128.54, 127.64, 126.79, 124.35, 123.78.
7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰胺基硫脲的制备方法,由以下合成路线制得:The preparation method of 7-benzo[b]-[1,10]o-phenanthroline pyridine carboxamide thiourea is prepared by the following synthetic route:
优选的是,所述7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰胺基硫脲的制备方法,具体步骤为:Preferably, the preparation method of the 7-benzo[b]-[1,10]-phenanthroline pyridinecarboxamide thiourea, the specific steps are:
步骤一,按照重量份在容器中加入20-30份邻溴苯甲酸和30-40份8-氨基喹啉作为原料,6-8份碳酸钾和0.2-0.4份铜粉为催化剂,加入20-50mL正戊醇或异戊醇作为溶剂,加热至130-150℃回流1.5-3小时,反应结束后,减压蒸除溶剂,然后向固体残留物中加入水继续继续反应15-30分钟,反应温度控制在70-90℃,过滤,将滤液调节pH,抽滤,得到化合物N-喹啉基邻氨基苯甲酸;Step 1, add 20-30 parts of o-bromobenzoic acid and 30-40 parts of 8-aminoquinoline in the container according to weight parts as raw materials, 6-8 parts of potassium carbonate and 0.2-0.4 parts of copper powder as catalysts, add 20- 50mL of n-amyl alcohol or isoamyl alcohol is used as a solvent, heated to 130-150°C and refluxed for 1.5-3 hours. After the reaction is completed, the solvent is evaporated under reduced pressure, and then water is added to the solid residue to continue the reaction for 15-30 minutes. Control the temperature at 70-90°C, filter, adjust the pH of the filtrate, and filter with suction to obtain the compound N-quinolyl anthranilic acid;
步骤二,将得到的化合物N-喹啉基邻氨基苯甲酸与7-7.5mL纯三氯氧磷混合,油浴加热,反应1-3小时,制得化合物7-氯苯并[b]-[1,10]邻菲咯啉;Step 2, mix the obtained compound N-quinolyl anthranilic acid with 7-7.5mL pure phosphorus oxychloride, heat in an oil bath, and react for 1-3 hours to obtain the compound 7-chlorobenzo[b]- [1,10] o-phenanthroline;
步骤三,在容器中加入0.2-0.4份所述化合物7-氯苯并[b]-[1,10]邻菲咯啉和25-35mL丙酮,回流溶解后加入0.275份硫氰化钠和0.0075份四丁基溴化铵,继续回流反应2-4小时,至有黄色固体粉末析出,抽滤,水洗得到化合物7-苯并[b]-[1,10]邻菲咯啉异硫氰酸酯;Step 3, add 0.2-0.4 parts of the compound 7-chlorobenzo[b]-[1,10]phenanthroline and 25-35mL acetone into the container, add 0.275 parts of sodium thiocyanate and 0.0075 Tetrabutylammonium bromide, continue to reflux reaction for 2-4 hours, until yellow solid powder precipitates, filter with suction, wash with water to obtain compound 7-benzo[b]-[1,10]phenanthroline isothiocyanate ester;
步骤四,在容器中加入0.2-0.3份将化合物7-苯并[b]-[1,10]邻菲咯啉异硫氰酸酯和20-40mL乙腈溶液,然后加入异烟肼,回流反应1-3小时,反应过程中有大量黄色粉末固体析出,抽滤洗涤后即得目标产物7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰胺基硫脲。Step 4, add 0.2-0.3 parts of the compound 7-benzo[b]-[1,10]phenanthroline isothiocyanate and 20-40mL acetonitrile solution in the container, then add isoniazid, reflux reaction After 1-3 hours, a large amount of yellow powder solids were precipitated during the reaction, and the target product 7-benzo[b]-[1,10]phenanthroline pyridine carboxamide thiourea was obtained after suction filtration and washing.
优选的是,所述7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰胺基硫脲的制备方法,所述步骤一中将滤液调节pH,向滤液中加入浓盐酸调节pH至1.5-2.5。Preferably, in the preparation method of the 7-benzo[b]-[1,10]phenanthroline pyridinecarboxamide thiourea, in the step 1, the pH of the filtrate is adjusted, and concentrated hydrochloric acid is added to the filtrate to adjust pH to 1.5-2.5.
优选的是,所述7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰胺基硫脲的制备方法,所述步骤二中化合物N-喹啉基邻氨基苯甲酸与三氯氧磷关环时,10-15min内油浴加热至85-90℃;当发生剧烈反应时,立即撤去热浴;若反应过于猛烈,可用冷水冷却烧瓶,待沸腾趋缓,油浴温度升高至135~140℃,反应1-3小时。Preferably, in the preparation method of the 7-benzo[b]-[1,10]phenanthroline pyridine carboxamide thiourea, the compound N-quinolyl anthranilic acid and three When phosphorus oxychloride is ring-closed, heat the oil bath to 85-90°C within 10-15 minutes; when a violent reaction occurs, remove the hot bath immediately; if the reaction is too violent, cool the flask with cold water until the boiling slows down and the temperature of the oil bath rises As high as 135-140°C, react for 1-3 hours.
优选的是,所述7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰胺基硫脲的制备方法,所述步骤二中反应结束后,将剩余物倒入重量比为1∶1-2∶1-2的浓氨水、碎冰和氯仿的混合物中,固体物溶解,分离出氯仿层,水层继续用氯仿萃取2-3次,合并氯仿提取液,干燥10-24小时,过滤,蒸除溶剂,即得到化合物7-氯苯并[b]-[1,10]邻菲咯啉。Preferably, in the preparation method of the 7-benzo[b]-[1,10]phenanthroline pyridine carboxamide thiourea, after the reaction in the step 2 is completed, the residue is poured into a weight ratio of In a 1:1-2:1-2 mixture of concentrated ammonia water, crushed ice, and chloroform, the solid matter was dissolved, and the chloroform layer was separated, and the aqueous layer was extracted with chloroform for 2-3 times, and the chloroform extract was combined and dried for 10-24 hours, filtered, and evaporated to remove the solvent to obtain the compound 7-chlorobenzo[b]-[1,10]phenanthroline.
7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰胺基硫脲在制备抗肿瘤药物中的应用。Application of 7-benzo[b]-[1,10]-phenanthroline pyridine carboxamide thiourea in the preparation of antitumor drugs.
本发明的有益效果是,本发明通过在苯并[b]-[1,10]邻菲咯啉环的7-位上连接活性基团酰胺基硫脲结构,合成新型吖啶衍生物,改进了吖啶衍生物对DNA的亲和性、多种酶的抑制性能和细胞毒性,为吖啶型抗肿瘤物提供了新的思路。The beneficial effects of the present invention are that the present invention synthesizes novel acridine derivatives by linking the active group amidothiourea structure at the 7-position of the benzo[b]-[1,10]phenanthroline ring, improving The affinity of acridine derivatives to DNA, the inhibitory properties of various enzymes and the cytotoxicity have been studied, which provides a new idea for acridine-type anti-tumor substances.
具体实施方式detailed description
实施例1Example 1
7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰胺基硫脲的制备Preparation of 7-benzo[b]-[1,10]phenanthroline pyridine carboxamide thiourea
步骤一,在250mL三颈瓶中,加入26g邻溴苯甲酸、34g(34mmoL)8-氨基喹啉、7.5g(36.2mmoL)碳酸钾和0.3g(4.7mmoL)铜粉,再加入30mL异戊醇作为溶剂,加热至140℃回流搅拌2h。反应结束后,减压蒸除溶剂,所得残留物加600mL水,控制温度在80℃反应20min,趁热过滤,洗涤滤饼,合并水层,水层用浓盐酸酸化至pH2,析出大量黑色粉末,抽滤,所得固体用丙酮重结晶,得到化合物N-喹啉基邻氨基苯甲酸,产率36%;Step 1, in a 250mL three-necked flask, add 26g o-bromobenzoic acid, 34g (34mmoL) 8-aminoquinoline, 7.5g (36.2mmoL) potassium carbonate and 0.3g (4.7mmoL) copper powder, then add 30mL isoamyl Alcohol was used as a solvent, heated to 140°C and stirred at reflux for 2h. After the reaction, evaporate the solvent under reduced pressure, add 600mL of water to the obtained residue, control the temperature at 80°C for 20 minutes, filter while it is hot, wash the filter cake, combine the water layer, acidify the water layer with concentrated hydrochloric acid to pH2, and precipitate a large amount of black powder , suction filtration, and the obtained solid was recrystallized with acetone to obtain the compound N-quinolyl anthranilic acid with a yield of 36%;
步骤二,在100mL圆底烧瓶中,加入得到的化合物N-喹啉基邻氨基苯甲酸(9moL)及7.2mL纯三氯氧磷,于15min内油浴上将反应物加热至85℃;当发生剧烈反应时,立即撤去热浴;若反应过于猛烈,可用冷水冷却烧瓶,待沸腾趋缓,油浴温度升高至135℃,反应2h。反应结束后,剩余物在冷却 后缓慢倾入充分搅拌的按照重量比为重量比为1∶1∶2的浓氨水、碎冰和氯仿的混合物中,用氯仿和氨水混合物洗涤烧瓶,30min后不再有未溶解的固体物,分离出氯仿层,水层继续用氯仿萃取3次,合并氯仿提取液,无水氯化钙干燥10小时,过滤,蒸除溶剂,得到化合物7-氯苯并[b]-[1,10]邻菲咯啉,产率18%;Step 2, in a 100mL round bottom flask, add the obtained compound N-quinolyl anthranilic acid (9moL) and 7.2mL of pure phosphorus oxychloride, and heat the reactant to 85°C on an oil bath within 15min; When a violent reaction occurs, remove the heat bath immediately; if the reaction is too violent, cool the flask with cold water, wait until the boiling slows down, raise the temperature of the oil bath to 135°C, and react for 2 hours. After the reaction was finished, the residue was slowly poured into a well-stirred mixture of concentrated ammonia water, crushed ice and chloroform in a weight ratio of 1:1:2 according to the weight ratio after cooling, and the flask was washed with a mixture of chloroform and ammonia water. After 30 minutes, no There are undissolved solids again, separate the chloroform layer, continue to extract the water layer with chloroform for 3 times, combine the chloroform extracts, dry with anhydrous calcium chloride for 10 hours, filter, and evaporate the solvent to obtain the compound 7-chlorobenzo[ b]-[1,10]-phenanthroline, yield 18%;
步骤三,在100mL圆底烧瓶中,加入0.3g(1.1mmoL)7-氯苯并[b]-[1,10]邻菲咯啉及30mL丙酮,回流溶解后加入0.275g NaSCN(3.3mmoL)和0.075g(0.23mmoL)四丁基溴化铵,回流反应3h后,有黄色固体粉末析出,抽滤,水洗涤后得到化合物7-苯并[b]-[1,10]邻菲咯啉异硫氰酸酯,94%;Step 3: In a 100mL round bottom flask, add 0.3g (1.1mmoL) 7-chlorobenzo[b]-[1,10]phenanthroline and 30mL acetone, and add 0.275g NaSCN (3.3mmoL) after refluxing to dissolve and 0.075g (0.23mmoL) tetrabutylammonium bromide, after reflux reaction for 3h, a yellow solid powder was precipitated, filtered by suction, and washed with water to obtain compound 7-benzo[b]-[1,10]phenanthroline Isothiocyanates, 94%;
步骤四,在100mL圆底烧瓶中,加入0.24g(0.8mmoL)化合物7-苯并[b]-[1,10]邻菲咯啉异硫氰酸酯和35mL乙腈,后加入1mmoL苯甲酰肼,回流反应2h,反应过程中有大量固体析出,冷却抽滤得金黄色固体即为7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰胺基硫脲,产率57.2%,m.p.175-181℃;1HNMR(DMSO-d6,400M Hz),δ:12.89(br,s,1H,-NH),12.41(br,s,1H,-NH),11.07(br,s,1H,-NH),10.99(s,1H,ArH),10.22(d,1H,J=9.0,ArH),9.09(d,1H,J=8.5,ArH),8.82(s,1H,ArH),8.64(d,2H,J=7.2,ArH),8.47(d,1H,J=7.2,ArH),8.24-8.36(m,2H,ArH),7.86-7.96(m,2H,ArH),7.83(d,1H,J=7.2,ArH),7.77(d,1H,J=7.2,ArH),7.66-7.74(m,2H,ArH);13C NMR(DMSO-d6,100MHz),δ189.70,170.21,150.34,149.89,145.21,134.38,133.78,133.42,132.18,131.29,130.55,130.21,129.67,129.27,128.54,127.64,126.79,124.35,123.78;该药物可以制成药学上的常见剂型,包括制成注射剂、片剂、丸剂、胶囊、悬浮剂或乳剂。Step 4, in a 100mL round bottom flask, add 0.24g (0.8mmoL) compound 7-benzo[b]-[1,10]phenanthroline isothiocyanate and 35mL acetonitrile, then add 1mmoL benzoyl Hydrazine, reflux reaction for 2h, a large amount of solids were precipitated during the reaction, and the golden yellow solid was obtained by cooling and suction filtration, which was 7-benzo[b]-[1,10]phenanthroline pyridine carboxamide thiourea, and the yield was 57.2 %, mp175-181°C; 1 HNMR (DMSO-d 6 , 400M Hz), δ: 12.89 (br, s, 1H, -NH), 12.41 (br, s, 1H, -NH), 11.07 (br, s , 1H, -NH), 10.99 (s, 1H, ArH), 10.22 (d, 1H, J=9.0, ArH), 9.09 (d, 1H, J=8.5, ArH), 8.82 (s, 1H, ArH) , 8.64 (d, 2H, J=7.2, ArH), 8.47 (d, 1H, J=7.2, ArH), 8.24-8.36 (m, 2H, ArH), 7.86-7.96 (m, 2H, ArH), 7.83 (d, 1H, J=7.2, ArH), 7.77 (d, 1H, J=7.2, ArH), 7.66-7.74 (m, 2H, ArH); 13 C NMR (DMSO-d 6 , 100MHz), δ189. 70, 170.21, 150.34, 149.89, 145.21, 134.38, 133.78, 133.42, 132.18, 131.29, 130.55, 130.21, 129.67, 129.27, 128.54, 127.64, 126.79, 124.78, 123. Made into injections, tablets, pills, capsules, suspensions or emulsions.
实施例2Example 2
体外抗肿瘤活性实验In vitro anti-tumor activity experiment
一、细胞的培养和传代1. Cell culture and passage
所选细胞株均置于37℃、5%CO2充分湿化条件下的培养箱中,接种于含10%灭活新生牛血清的PPMI1640培养液中培养。用倒置显微镜观察细胞生长情况,每周更换2~3次培养基,6~7天传代一次,接种时以0.25%胰蛋白酶消化传代,通常取传代3~4次,处于对数生长期细胞用于实验。The selected cell lines were all placed in an incubator at 37°C and fully humidified with 5% CO2, and inoculated in PPMI1640 medium containing 10% inactivated newborn bovine serum for culture. Use an inverted microscope to observe the growth of the cells, replace the medium 2-3 times a week, passage once every 6-7 days, digest and passage with 0.25% trypsin when inoculating, usually take 3-4 passages, and use it for cells in the logarithmic growth phase in the experiment.
二、药液的配制2. Preparation of liquid medicine
准确称取被测样品,加到灭菌的1.5mL离心管中,加入DMSO配成2mM化合物储备液,-20℃冷冻保存。临用前融化后用适量D-hanks稀释成相应浓度应用。实验测定选用的化合物浓度分别为20uM。Accurately weigh the sample to be tested, add it to a sterilized 1.5mL centrifuge tube, add DMSO to make a 2mM compound stock solution, and store it in a freezer at -20°C. Dilute with appropriate amount of D-hanks to the corresponding concentration after melting before use. The concentrations of the selected compounds were determined to be 20 uM.
三、MTT实验方法3. MTT experimental method
取处于对数生长期的细胞,每孔180uL(约4500-5000个细胞)含细胞的培养基接种于96孔培养板,于37℃、5%CO2充分湿化条件下培养24h。待细胞贴壁后,按每孔20uL的量加入样品,每个样品设6个复孔,同时设定相应的空白对照。继续培养48h后,每孔加入10uLMTT试剂(浓度为2mg/mL),继续孵育4h后,吸弃上清液,每孔再加入150uL DMSO,轻微震荡反应5-8min,使结晶颗粒充分溶解。空白对照组调零,用酶标仪以490nm波长测定去除本底光吸收值后的吸光度值(值),用5个浓度梯度做相应细胞株的IC50值,所有实验均重复3次后取平均值。Take the cells in the logarithmic growth phase, inoculate 180uL (about 4500-5000 cells) of cell-containing medium per well on a 96-well culture plate, and culture them at 37°C and 5% CO under fully humidified conditions for 24h. After the cells adhered to the wall, add samples in an amount of 20 uL per well, set 6 duplicate wells for each sample, and set corresponding blank controls at the same time. After continuing to culture for 48 hours, add 10uL MTT reagent (concentration: 2mg/mL) to each well. After continuing to incubate for 4h, discard the supernatant, add 150uL DMSO to each well, and shake gently for 5-8min to fully dissolve the crystal particles. The blank control group was adjusted to zero, and the absorbance value ( value), the IC50 values of the corresponding cell lines were made with 5 concentration gradients, and all experiments were repeated 3 times to obtain the average value.
表1 7-苯并[c]吖啶苯甲酰胺基硫脲对肿瘤细胞株的半数有效浓度(IC50)Table 1 The half effective concentration (IC 50 ) of 7-benzo[c]acridinebenzamide thiourea on tumor cell lines
表1Table 1
从实施例2的结果可以看出,本发明的7-苯并[b]-[1,10]邻菲咯啉吡啶甲酰胺基硫脲经体外抗肿瘤实验表明,该化合物具有强的抗肿瘤活性。本发明为研究开发新的吖啶型抗肿瘤药物提供了新的思路。As can be seen from the results of Example 2, the 7-benzo[b]-[1,10]phenanthroline pyridine carboxamide thiourea of the present invention shows through in vitro antitumor experiments that the compound has strong antitumor active. The invention provides a new idea for researching and developing new acridine type antitumor drugs.
尽管本发明的实施方案已公开如上,但其并不仅仅限于说明书和实施方式中所列运用,它完全可以被适用于各种适合本发明的领域,对于熟悉本领域的人员而言,可容易地实现另外的修改,因此在不背离权利要求及等同范围所限定的一般概念下本发明并不限于特定的细节。Although the embodiment of the present invention has been disclosed as above, it is not limited to the use listed in the specification and implementation, it can be applied to various fields suitable for the present invention, and it can be easily understood by those skilled in the art Therefore, the invention is not limited to specific details without departing from the general concept defined by the claims and their equivalents.
Claims (6)
- A kind of 1. 7- benzos [b]-[1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide, it is characterised in that the acridine derivatives Structural formula be:The 7- benzos [b]-[1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide Preparation method, concretely comprise the following steps:Step 1,20-30 parts o-bromobenzoic acid and 30-40 part 8- aminoquinolines are added in a reservoir according to parts by weight as former Material, 6-8 parts potassium carbonate and 0.2-0.4 parts copper powder be catalyst, and then addition 20-50mL n-amyl alcohols or isoamyl alcohol be as solvent, 130-150 DEG C of backflow 1.5-3 hour is heated to, after reaction terminates, solvent is removed under reduced pressure, water is then added into solid residue Continue to react 15-30 minutes, reaction temperature is controlled at 70-90 DEG C, filtering, filtrate is adjusted into pH, is filtered, is obtained compound N- quinolyl ortho-aminobenzoic acids;Step 2, obtained compound N-quinolyl ortho-aminobenzoic acid is mixed with the pure POCl3s of 7-7.5mL, oil bath adds Heat, 1-3 hours are reacted, compound 7- chlorobenzenes simultaneously [b]-[1,10] o-phenanthroline is made;Step 3,0.2-0.4 parts compound 7- chlorobenzenes simultaneously [b]-[1,10] o-phenanthroline and 25-35mL are added in a reservoir Acetone, 0.275 part of sodium sulfocynanate and 0.0075 part of TBAB are added after backflow dissolving, continues back flow reaction 2-4 hours, To there is the precipitation of yellow solid powder, filter, washing obtains compound 7- benzos [b]-[1,10] o-phenanthroline isothiocyanates;Step 4, add in a reservoir 0.2-0.3 parts by compound 7- benzos [b]-[1,10] o-phenanthroline isothiocyanates and 20-40mL acetonitriles, then add isoniazid, back flow reaction 1-3 hours, have a large amount of yellow powder solids to separate out in course of reaction, Target product 7- benzos [b]-[1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide is produced after filtering and washing.
- 2. a kind of preparation method of 7- benzos [b]-[1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide as claimed in claim 1, Characterized in that, it is made by following synthetic route:
- 3. the preparation method of 7- benzos [b] as claimed in claim 1-[1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide, it is special Sign is, filtrate is adjusted into pH in the step 1, and concentrated hydrochloric acid regulation pH to 1.5-2.5 is added into filtrate.
- 4. the preparation method of 7- benzos [b] as claimed in claim 1-[1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide, it is special Sign is, when compound N-quinolyl ortho-aminobenzoic acid is with POCl3 cyclization in the step 2, oil bath in 10-15min It is heated to 85-90 DEG C;When vigorous reaction occurs, heating bath is removed immediately;If reaction is excessively fierce, flask can be cooled down with cold water, Treat that boiling eases up, oil bath temperature is increased to 135~140 DEG C, reacts 1-3 hours.
- 5. the preparation method of 7- benzos [b] as claimed in claim 4-[1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide, it is special Sign is, after reaction terminates in the step 2, residue is poured into weight ratio for 1:1-2:1-2 concentrated ammonia liquor, trash ice and chlorine In imitative mixture, solids dissolving, chloroform layer is isolated, water layer continues to be extracted 2-3 times with chloroform, merges chloroform extracted solution, 10-24 hours are dried, filtering, solvent is evaporated off, that is, obtains compound 7- chlorobenzenes simultaneously [b]-[1,10] o-phenanthroline.
- A kind of 6. 7- benzos [b]-application of [1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide in antineoplastic is prepared.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510870314.1A CN105418608B (en) | 2015-12-02 | 2015-12-02 | 7 benzos [b] [1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide and its production and use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510870314.1A CN105418608B (en) | 2015-12-02 | 2015-12-02 | 7 benzos [b] [1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide and its production and use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105418608A CN105418608A (en) | 2016-03-23 |
CN105418608B true CN105418608B (en) | 2017-11-14 |
Family
ID=55497204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510870314.1A Active CN105418608B (en) | 2015-12-02 | 2015-12-02 | 7 benzos [b] [1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide and its production and use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105418608B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104326979A (en) * | 2014-09-30 | 2015-02-04 | 广西中医药大学 | 2-methyl-9-acridine(p-methoxy benzamido)thiourea, preparation method and uses thereof |
CN104327050A (en) * | 2014-09-30 | 2015-02-04 | 广西中医药大学 | Acridine amide thiourea derivative, preparation method and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015142684A1 (en) * | 2014-03-15 | 2015-09-24 | Wake Forest University | Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith |
-
2015
- 2015-12-02 CN CN201510870314.1A patent/CN105418608B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104326979A (en) * | 2014-09-30 | 2015-02-04 | 广西中医药大学 | 2-methyl-9-acridine(p-methoxy benzamido)thiourea, preparation method and uses thereof |
CN104327050A (en) * | 2014-09-30 | 2015-02-04 | 广西中医药大学 | Acridine amide thiourea derivative, preparation method and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN105418608A (en) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104955811B (en) | Deuterated phenyl amino pyrimidine compounds and the pharmaceutical composition comprising the compound | |
CN102206203B (en) | Synthesis of Naphthalimide Derivatives Containing Benzimidazole and Its Application in Antitumor | |
CN104326979B (en) | 2-methyl-9-acridine (to methoxy benzamide base) thiocarbamide and its production and use | |
CN101723890B (en) | Arylthiourea and its preparation method and use | |
CN105705493A (en) | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | |
CN104327050B (en) | A kind of acridinium carboxamide base thiourea derivatives and its production and use | |
CN105418608B (en) | 7 benzos [b] [1,10] o-phenanthroline pyridinecarboxylic amido thiocarbamide and its production and use | |
CN105481852B (en) | 7 benzos [b] [1,10] o-phenanthroline is to methoxy benzamide base thiocarbamide and its production and use | |
CN113979995A (en) | MEK inhibitor and application thereof in medicine | |
CN113493443A (en) | Erlotinib derivative with killing performance on wild lung cancer tumor cells and preparation method thereof | |
CN104059062B (en) | Condensed Ring Compounds Containing Benzothiazole and Triazole Biheterocycles and Their Applications | |
CN108840868B (en) | The preparation method and application of trypoline ketone compounds with anti-tumor activity | |
CN106243089B (en) | 6- substitutions -2- (benzimidazolyl-2 radicals-methylene sulfenyl) pyrimidines of 4 construction units containing chalcone and its preparation method and application | |
CN108864089A (en) | A kind of new indole and pyridone drug molecule and its preparation method and application | |
CN113956234A (en) | N-phenyl substituted 1H-indazole-3-amine compound, preparation thereof and application thereof in antitumor activity | |
CN102216280A (en) | Bisaryl urea derivatives and their uses | |
CN109879887A (en) | Thieno[3,2-d]pyrimidine derivatives containing indole structure and their applications | |
CN104327064B (en) | Acridine-1,3,4-oxadiazole compound having anti-tumor activity, preparation method and uses thereof | |
CN103130803B (en) | Oxidized iso-aporphine alkaloid derivative, synthetic method and application | |
CN110590724B (en) | 4-arylpyran derivative containing aryl urea and application thereof | |
CN104327063B (en) | Acridine oxadiazole derivative, preparation method and uses thereof | |
CN105399740B (en) | Acridine derivatives and preparation method thereof and it is used as the purposes in antineoplastic | |
CN108727400A (en) | A kind of compound for treating tumour | |
CN119504793A (en) | A dihydropyrimidine derivative containing bithiazolinone and its preparation method and application | |
CN102010408A (en) | 3- [4- (benzofuran-5-yl) thiazole-2-yl ] -2-methylbenzimidazole-5-formic ether and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200415 Address after: 314500 room 503, building 3, No.133, development avenue, Tongxiang Economic Development Zone, Tongxiang City, Jiaxing City, Zhejiang Province Patentee after: ZHEJIANG MAIZHI NETWORK TECHNOLOGY Co.,Ltd. Address before: 13 No. 530213 the Guangxi Zhuang Autonomous Region Nanning Qingxiu District five Avenue Patentee before: Guangxi University of Chinese Medicine |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231124 Address after: Room 343-3, Building 1, Guomao Center, Honghe Town, Xiuzhou District, Jiaxing City, Zhejiang Province, 314500 Patentee after: Jiaxing Zhuoshi Biotechnology Co.,Ltd. Address before: Room 503, building 3, No. 133, development avenue, Tongxiang Economic Development Zone, Tongxiang City, Jiaxing City, Zhejiang Province Patentee before: ZHEJIANG MAIZHI NETWORK TECHNOLOGY CO.,LTD. |